As use of glucagon-like peptide-1 receptor agonist (GLP-1) medications increased between 2022 and 2025, the volume of metabolic and bariatric surgeries (MBS) declined by 46.4% over three years, according to a recent study. Among people eligible for MBS, GLP-1 prescription rates increased from 0.22% in 2018 to 24.17% in the third quarter of 2025.

The study analyzed trends in the use of GLP-1 medications and bariatric surgery among adults eligible for MBS using electronic health record data.

MBS declined by 35% among those with a body mass index (BMI) of 55 or . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

The News

Daily coverage of the developments shaping health and human services. From policy shifts to program innovations, reports on trends-shaping mental health, addiction treatment, child and family services, autism and I/DD, disability support and long-term care, social services, corrections, juvenile justice, chronic disease management, health care systems, and more-helping leaders make timely, informed decisions.

Filter Options

  • By Market
  • By Topic
  • By Date Range
  • Sort Date By
  • Results Per Page
Clear Filters